2026-05-05T09:20:27Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/647172024-01-18T20:01:30Zcom_10324_1181com_10324_931com_10324_894col_10324_1387

00925njm 22002777a 4500 dc Natera-de Benito, Daniel author Aguilera-Albesa, Sergio author Costa-Comellas, Laura author García-Romero, Mar author Miranda-Herrero, María Concepción author Rúbies Olives, Júlia author García-Campos, Óscar author Martínez del Val, Elena author Martinez Garcia, Maria Josefa author Medina Martínez, Inmaculada author Fernandez-Garcia, Miguel A. author Pascual-Pascual, Samuel Ignacio author Gómez-Andrés, David author Nascimento, Andres author Camacho, Ana author Ortez, Carlos author Madruga, Marcos author Munell, Francina author Martí, Itxaso author Pitarch, Inmaculada author Domingo Jiménez, Maria Rosario author Iglesias Escalera, Gema author Fernández Ramos, Joaquin author Gómez Garcia-de la Banda, Marta author Ghandour, Diana author Grimalt, María Antonia author Nogales, Gisela author Alvarez Molinero, Mireia author 2021 Objective Children with neuromuscular disorders have been assumed to be a particularly vulnerable population since the beginning of COVID-19. Although this is a plausible hypothesis, there is no evidence that complications or mortality rates in neuromuscular patients are higher than in the general population. The aim of this study is to describe the clinical charac teristics and outcome of COVID-19 in children with neuromuscular disorders. Methods A registry of children with neuromuscular conditions and laboratory-confrmed-SARS-CoV-2 infection was set up by the Neuromuscular Working Group of the Spanish Pediatric Neurology Society (SENEP). Data to be collected were focused on the characteristics and baseline status of the neuromuscular condition and the course of COVID-19. Results Severe complications were not observed in our series of 29 children with neuromuscular disorders infected by SARS-CoV-2. Eighty-nine percent of patients were clinically categorized as asymptomatic or mild cases and 10% as moderate cases. Patients with a relatively more severe course of COVID-19 had SMA type 1 and were between 1 and 3 years. Conclusions The course of COVID-19 in children with neuromuscular disorders may not be as severe as expected. The protective role of young age seems to outweigh the risk factors that are common in neuromuscular patients, such as a decreased respiratory capacity or a weak cough. Further studies are needed to know if this finding can be generalized to children with other chronic diseases Journal of Neurology. 2021 0340-5354 https://uvadoc.uva.es/handle/10324/64717 10.1007/s00415-020-10339-y 3081 9 3085 Journal of Neurology 268 1432-1459 COVID-19 in children with neuromuscular disorders